Barclays Reiterates Overweight Rating on Alnylam Pharmaceuticals, Inc. (ALNY)

Market Context

Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $205.52 with a market capitalization of $44.2B. The stock has declined 39.5% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alnylam Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Alnylam Pharmaceuticals, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 03, 2026	Barclays	Overweight	N/A
Jul 31, 2026	Oppenheimer	Outperform	N/A
Jul 31, 2026	Morgan Stanley	Equal-Weight	N/A
Jul 31, 2026	RBC Capital	Outperform	N/A
Jul 31, 2026	JP Morgan	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View ALNY Stock Page